Could Restoring the Brain’s Resilience Help Reverse Alzheimer’s?

What did the researchers discover?

The study, published in Cell Reports Medicine, examined P7C3-A20 in two genetically engineered mouse models of Alzheimer’s disease. One model, known as 5xFAD, develops extensive amyloid-related disease. The other, PS19, develops disease driven primarily by abnormal tau, the second protein strongly associated with Alzheimer’s.

In the principal experiment, treatment of the 5xFAD mice began when they were six months old, after cognitive impairment and substantial disease-related changes were already present. The mice then received daily injections for six months.

By the end of treatment, the researchers reported improvements across an unusually broad range of measures:

• Memory and spatial learning returned approximately to the level of healthy mice on the tests used.
• Synaptic plasticity, the ability of connections between brain cells to strengthen and support learning, was restored.
• Abnormal tau phosphorylation declined.
• Neuroinflammation, oxidative stress and DNA damage were reduced.
• The integrity of the blood-brain barrier improved.
• The formation of new neurons in the hippocampus increased.
• Plasma p-tau217, an important Alzheimer’s biomarker, moved toward normal.
• Some structurally mature amyloid plaques were reduced.

The compound also produced beneficial results in the tau-driven PS19 mice. That is important because it suggests that the effects were not limited to a single model or exclusively to amyloid pathology.

The researchers described the behavioral result as “full cognitive recovery.” Within the confines of the mouse tests, that description is understandable: treated animals performed approximately as well as healthy controls. It should not, however, be interpreted as evidence that the treatment can fully restore memory, judgment or day-to-day functioning in a person with Alzheimer’s disease.

Why NAD+ matters

At the center of the research is nicotinamide adenine dinucleotide, better known as NAD+. This naturally occurring molecule is essential to life and is present in every cell.

NAD+ helps cells:

• Convert nutrients into usable energy
• Maintain healthy mitochondrial function
• Repair damaged DNA
• Regulate inflammation and oxidative stress
• Preserve the blood-brain barrier
• Maintain communication between neurons
• Survive periods of metabolic and cellular stress

The study found that the balance between NAD+ and its reduced form, NADH, deteriorated as disease advanced in the mice. P7C3-A20 appeared to restore this balance by supporting NAMPT, a key enzyme the body uses to recycle nicotinamide into NAD+.

This is a subtle but critical distinction. The objective was not simply to force NAD+ levels as high as possible. It was to restore NAD+ homeostasis, meaning the healthy balance and regulation of NAD+ within cells.

A different way of thinking about Alzheimer’s treatment

Much of Alzheimer’s drug development has focused on amyloid, the protein that accumulates in plaques between brain cells. Recently approved anti-amyloid antibodies can remove amyloid and modestly slow cognitive decline in some people with early Alzheimer’s disease. They do not stop the disease, restore lost cognition or address all the other biological processes involved.

P7C3-A20 represents a different and potentially complementary strategy. Instead of treating Alzheimer’s as though it were caused by one piece of biological debris, it seeks to reinforce the systems that allow the brain to cope with damage.

This matters because Alzheimer’s is not simply a problem of amyloid accumulation. It also involves abnormal tau, impaired energy metabolism, mitochondrial dysfunction, inflammation, vascular damage, oxidative stress, compromised DNA repair and the breakdown of communication between neurons. These processes interact and may intensify one another.

If restoring NAD+ homeostasis improves several of these systems simultaneously, it could affect the disease more broadly than a treatment directed at a single target.

An analogy may help. Removing amyloid is somewhat like removing debris from a damaged building. That may be necessary, but removing debris does not restore electricity, repair the plumbing or reinforce the structure. P7C3-A20 appears, at least in mice, to help reactivate some of the brain’s maintenance and repair systems.

The drug did not simply eliminate amyloid

The findings require an important qualification. P7C3-A20 did not stop the mice from producing amyloid-beta, nor did it substantially reduce all measured forms of the protein.

Although staining for certain mature amyloid structures declined, the treatment did not significantly reduce amyloid precursor protein or the measured quantities of soluble and insoluble Aβ40 and Aβ42. It therefore did not switch off the genetic machinery driving amyloid production in these animals.

Instead, the treatment appeared to improve the brain’s response to the continuing pathology. That may be more interesting than simply lowering an amyloid measurement. It suggests that cognitive impairment may be influenced not only by how much pathology is present, but also by how successfully the brain can tolerate, contain and repair the resulting damage.

What did the researchers learn from human brains?

No human patient received P7C3-A20 in this study. The human portion of the research involved brain tissue collected after death.

The researchers found that more severe Alzheimer’s disease was associated with greater disruption of pathways related to NAD+ homeostasis. They also examined tissue from an intriguing group of people who had substantial Alzheimer’s neuropathology at death but had remained cognitively intact during life.

These unusually resilient individuals showed patterns of gene expression consistent with better-preserved NAD+ regulation. That observation supports the idea that some brains may be better able to tolerate Alzheimer’s pathology.

It does not prove that disrupted NAD+ metabolism causes Alzheimer’s disease or that correcting it will reverse dementia in people. Postmortem tissue can reveal associations, but it cannot show what came first or demonstrate that a treatment will work.

This is not evidence that NAD+ supplements reverse Alzheimer’s

P7C3-A20 should not be confused with commercially available NAD+ products or precursors such as nicotinamide riboside, commonly called NR, or nicotinamide mononucleotide, known as NMN.

P7C3-A20 is an experimental pharmaceutical compound intended to help regulate the NAD+ recycling pathway within the brain. NR and NMN provide material the body can use to produce NAD+, but their effects vary among tissues, and increasing NAD-related compounds in the blood does not establish that the brain’s intracellular balance has been restored.

A 2026 randomized pilot study illustrates the difference. Nicotinamide riboside approximately doubled blood NAD+ in older adults with amnestic mild cognitive impairment, but it did not improve cognition, total cerebral blood flow or blood pressure during the 12-week trial. Exploratory findings suggested possible changes in blood flow in certain brain regions, but these require further study.

The P7C3-A20 findings therefore do not demonstrate that taking NR, NMN, niacinamide or intravenous NAD+ will prevent or reverse Alzheimer’s disease.

An important safety question

A critical consideration in developing P7C3-A20 will be finding a dose and delivery method that restore NAD+ to its normal physiological balance without pushing it above that range.

NAD+ supports energy production and DNA repair in healthy cells, but malignant cells use those same systems. Researchers have therefore raised the possibility that excessive NAD+ enhancement could help an existing tumor survive, grow or resist treatment. This has been observed in some laboratory and animal models, but NAD+ precursor supplements have not been shown to cause cancer in humans, and their long-term cancer-related safety remains uncertain.

This concern does not invalidate the treatment strategy. It means that regulated restoration is fundamentally different from indiscriminately increasing NAD+. Any future human development will require careful dosing, toxicology studies and long-term monitoring.

Why optimism must remain measured

There are substantial reasons for caution:

• P7C3-A20 has not been shown to treat Alzheimer’s disease in humans.
• Its safety, effective dose and long-term effects in people have not been established.
• Genetically engineered mice reproduce selected features of Alzheimer’s, not the full complexity of the human disease.
• The treatment required daily injections for six months.
• Some laboratory analyses involved relatively small numbers of animals.
• The findings have not yet been independently replicated.
• Several researchers hold related patents, and the senior author is a cofounder of a brain-health biotechnology company.

Patent and commercial interests do not make the results untrustworthy, but they make transparency and independent confirmation especially important.

Why I still find this research heartening

Despite those cautions, I find this research unusually encouraging. It suggests that a brain affected by substantial Alzheimer’s-like pathology may retain more capacity for functional recovery than we have assumed.

Equally important, the treatment does not focus solely on one visible manifestation of the disease. It seeks to restore the brain’s underlying ability to withstand cellular stress, maintain energy production, protect its blood vessels, repair damage and preserve communication among neurons. That is a more comprehensive way of thinking about Alzheimer’s disease.

I am also cautiously optimistic because P7C3-A20 is a potentially patentable pharmaceutical compound. Developing a neurological drug through toxicology studies, human trials and regulatory review is extraordinarily expensive. The possibility of a commercially viable treatment may attract the investment required to move the research forward. At the same time, that financial incentive makes rigorous independent testing essential.

The bottom line

This study did not demonstrate that Alzheimer’s disease can now be reversed in people. It demonstrated something narrower, but still potentially profound: restoring carefully regulated NAD+ metabolism produced broad pathological improvement and cognitive recovery in two mouse models of established Alzheimer’s-like disease.

That makes P7C3-A20 a compelling candidate for further research, not a treatment ready for patients. The next steps should include independent replication, comprehensive safety testing, development of a practical delivery method and, if those stages are successful, carefully controlled human trials.

For families living with Alzheimer’s today, this discovery does not change available treatment. But it does challenge the assumption that an impaired brain is necessarily beyond meaningful repair. In a field where progress is usually measured by how slowly decline can be delayed, credible evidence of recovery in an animal model deserves serious attention, careful scrutiny and guarded hope.